CRISPR Therapeutics AG

Listed Company

CRSPCIK 0001674416NasdaqLarge AcceleratedBiological Products, (No Diagnostic Substances)V8CHFY ends Dec 31

Period

FY 2025

Revenue

$3.51M

Net Income

$-581.60M

Total Assets

$2.27B

Equity

$1.92B

Shares Out

96.45M

Op. Cash Flow

$-345.01M

CRSP$47.81−13.13% · past yearDBEQ Basic

Daily closing prices

Business

CRISPR Therapeutics AG is a biopharmaceutical company developing CRISPR-based gene-editing therapeutics across hemoglobinopathies, in vivo editing, CAR T cell therapy, and regenerative medicine. Its lead product, CASGEVY, is the first approved CRISPR-based therapy, co-developed and co-commercialized with Vertex Pharmaceuticals for sickle cell disease and beta thalassemia. The company leverages both ex vivo (editing cells outside the body) and in vivo (direct delivery to target tissues) approaches, supported by internal manufacturing and strategic partnerships with Vertex and Sirius Therapeutics.

Summary from 10-K filed 2026-02-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	4	37	371	1	915
Research and development	285	310	387	462	341
Acquired in-process research and development	96	0	0	—	—
General and administrative	74	73	76	102	100
Collaboration expense, net	213	121	130	110	101
Total operating expenses	668	504	594	674	541
Loss from operations	−665	−467	−223	−673	374
Other income, net	87	104	72	23	6
Total other income, net	87	104	72	23	6
Net loss before income taxes	−578	−363	−151	−651	380
Provision for income taxes	−4	−4	−3	325,000	−2
Net loss	−582	−366	−154	−650	378
Foreign currency translation adjustment	95,000	−21,000	73,000	−80,000	−11,000
Unrealized gain (loss) on marketable securities	3	−52,000	17	−11	−5
Comprehensive loss	−579	−366	−136	−661	373
Net loss per common share - basic	−6.47	−4.34	−1.94	−8.36	4.97
Basic weighted-average common shares outstanding	90	84	79	78	76
Net loss per common share - diluted	−6.47	−4.34	−1.94	−8.36	4.7
Diluted weighted-average common shares outstanding	90	84	79	78	80

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	348	298	389	212	923
Marketable securities	1,628	1,606	1,304	1,603	1,456
Accounts receivable	0	25	200	0	305,000
Prepaid expenses and other current assets	10	8	14	38	38
Total current assets	1,986	1,937	1,908	1,853	2,418
Property and equipment, net	116	134	152	164	138
Restricted cash	8	12	12	12	17
Operating lease assets	132	143	154	157	174
Other non-current assets	24	16	2	5	5
Total assets	2,265	2,242	2,230	2,243	2,752
Accounts payable	11	15	38	27	15
Accrued expenses	89	41	45	78	91
Deferred revenue, current	16	4	4	0	1
Accrued tax liabilities	1	451,000	438,000	135,000	724,000
Operating lease liabilities	19	17	16	16	12
Other current liabilities	13	10	5	20,000	171,000
Total current liabilities	149	88	109	121	120
Deferred revenue, non-current	0	12	14	12	12
Operating lease liabilities, net of current portion	188	206	223	228	213
Other non-current liabilities	6	3	958,000	6	7
Total liabilities	343	310	347	368	352
Commitments and contingencies (Note 9)	—	—	—	—	—
Common shares, CHF 0.03 nominal value, 132,477,166 shares authorized at December 31, 2025 and December 31, 2024, 96,009,657 and 85,912,297 shares issued at December 31, 2025 and December 31, 2024, respectively, 95,894,341 and 85,741,981 shares outstanding at December 31, 2025 and December 31, 2024, respectively	3	3	2	2	2
Treasury shares, at cost, 115,316 and 170,316 shares at December 31, 2025 and December 31, 2024, respectively	−60,000	−62,000	−62,000	−63,000	−63,000
Additional paid-in capital	3,862	3,294	2,878	2,735	2,598
Accumulated deficit	−1,948	−1,366	−1,000	−846	−196
Accumulated other comprehensive income	5	2	2	−16	−5
Total shareholders equity	1,922	1,932	1,883	1,875	2,399
Total liabilities and shareholders equity	2,265	2,242	2,230	2,243	2,752

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−582	−366	−154	−650	378
Depreciation and amortization	19	19	20	24	18
Stock-based compensation expense	72	87	81	98	102
Other non-cash items, net	−24	−39	−17	12	14
Acquired in-process research and development	—	—	3	—	—
Accounts receivable	25	175	−200	305,000	−161,000
Prepaid expenses and other assets	3	5	23	2	−14
Accounts payable and accrued expenses	45	−27	−20	5	38
Deferred revenue	−397,000	−2	6	−1	−783,000
Operating lease assets and liabilities	−5	−4	−2	15	10
Other liabilities, net	4	10	110,000	−2	−5
Net cash used in operating activities	−345	−143	−260	−496	539
Purchase of property, plant and equipment	−914,000	−2	−9	−37	−82
Purchase of in-process research and development	−25	0	−3	0	0
Investment in equity securities	−10	−23	0	0	—
Sale of equity securities	702,000	0	0	—	—
Purchases of marketable debt securities	−1,008	−1,463	−1,066	−1,418	−1,509
Maturities of marketable debt securities	1,011	1,208	1,453	1,196	556
Net cash used in (provided by) investing activities	−32	−280	375	−259	−1,035
Proceeds from issuance of common shares, net of issuance costs	398	301	33	970,000	213
Proceeds from exercise of options and ESPP contributions, net of issuance costs	28	31	30	38	38
Net cash provided by financing activities	426	332	63	39	251
Effect of exchange rate changes on cash	95,000	−21,000	73,000	−80,000	−11,000
Increase (decrease) in cash	49	−91	177	−716	−246
Property and equipment purchases in accounts payable and accrued expenses	394,000	154,000	725,000	2	8
Equity issuance costs in accounts payable and accrued expenses	5	3	417,000	99,000	334,000
Acquired in-process research and development expense related to issuance of common shares	71	0	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is CRISPR Therapeutics AG's CIK number?

CRISPR Therapeutics AG's SEC CIK number is 0001674416 (1674416). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find CRISPR Therapeutics AG's SEC filings?

All of CRISPR Therapeutics AG's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did CRISPR Therapeutics AG last report earnings?

CRISPR Therapeutics AG (CRSP) most recently filed an earnings 8-K with the SEC on May 4, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-204147). This is CRISPR Therapeutics AG's most recent earnings filing of record — not a forecast of its next earnings date.

What is CRISPR Therapeutics AG's most recent earnings 8-K?

CRISPR Therapeutics AG's latest earnings 8-K (Item 2.02) was filed May 4, 2026 under accession 0001193125-26-204147. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View CRISPR Therapeutics AG's latest earnings 8-K →
Look up any company's CIK number →